Gilead CFO Executes 10b5-1 Sale: 2,500 Shares Disposed on 09/15/2025

Rhea-AI Filing Summary

Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported a sale of 2,500 shares of Gilead common stock on 09/15/2025 at a price of $113.57 per share, reducing his beneficial holdings to 159,555 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the transaction was prearranged. The Form 4 was signed by a power of attorney on behalf of Mr. Dickinson on 09/16/2025. No derivative transactions or other types of securities are reported in this filing.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating the trade was prearranged and reducing concerns about opportunistic timing
• Small transaction size (2,500 shares) relative to the remaining holding of 159,555 shares, suggesting limited immediate impact

Negative

• None.

Insights

Securities Analyst

TL;DR: A small, prearranged insider sale under a 10b5-1 plan reduced the CFO's stake to 159,555 shares.

The sale of 2,500 shares at $113.57 represents a modest, routine disposition relative to an executive-level holding. Because the filing discloses the transaction occurred under a Rule 10b5-1 trading plan adopted in August 2024, this indicates the trade was pre-scheduled and not necessarily a reaction to recent material nonpublic information. The size of the sale (2,500 shares) is small versus the remaining stake, suggesting limited immediate impact on market sentiment or control metrics. For investors, this is a disclosure of routine insider liquidity rather than a material corporate development.

Corporate Governance Expert

TL;DR: Preplanned insider sale aligns with governance best practices but warrants routine monitoring of insider activity.

The transaction conforms to governance norms by using a documented Rule 10b5-1 plan, which helps mitigate concerns about opportunistic timing. The filing is complete for the reported non-derivative sale and includes the required signature via power of attorney. While the sale itself is not large enough to signal governance issues, continued patterns of sales or changes in plan adoption timing could merit closer scrutiny by investors and governance committees.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		S(1)		2,500	D	$113.57	159,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in the this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Andrew D. Dickinson (GILD) report on Form 4?

The CFO reported a sale of 2,500 shares of Gilead common stock on 09/15/2025 at $113.57 per share, leaving 159,555 shares beneficially owned.

Was the sale by GILD's CFO part of a 10b5-1 trading plan?

Yes. The Form 4 states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Did the Form 4 report any option exercises or derivative transactions for GILD?

No. The filing lists only a non-derivative sale of common stock and reports no derivative securities.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of Andrew D. Dickinson by Edward S. Son via power of attorney on 09/16/2025.

How much cash did the reported sale generate?

The sale of 2,500 shares at $113.57 per share generated gross proceeds of $283,925.